PercAssist’s Novel Circulatory Support Presented at TCT24
PercAssist, Inc., a groundbreaking medical device company, recently showcased its innovative Percutaneous Synchronized Cardiac Assist (PSCA) System at the prestigious Transcatheter Cardiovascular Therapeutics (TCT24) Conference. This incredible technology focuses on providing mechanical circulatory support to patients suffering from cardiogenic shock (CS), a life-threatening condition affecting heart function.
Understanding Cardiogenic Shock and MCS
Cardiogenic shock occurs when the heart is unable to pump enough blood to meet the body’s needs. This often leads to organ failure and, if not treated effectively, can be fatal. Conventional treatment options sometimes come with significant risks, including major bleeding or complications from vascular access. This is where PercAssist steps in with their unique PSCA System, designed to circumvent some of these issues.
Innovative Technology at TCT24
At TCT24, which was held over several days in late October, PercAssist had the opportunity to share its latest research findings. Gerardo Noriega, the president and CEO of PercAssist, expressed pride in presenting the PSCA Technology. He emphasized that the system's extravascular, intrapericardial approach offers a safer alternative by eliminating the need for large vessel access.
Promising Clinical Results
Engaging in conversation about the recent data, Noriega pointed out the excitement surrounding the encouraging results from both pre-clinical trials and first-in-human studies. Current findings suggest that the PSCA System can effectively alleviate critical complications associated with traditional treatment methods, including hemolysis and stroke.
Highlighting Clinical Sessions
During TCT24, the PSCA System was highlighted at several key presentations, including the TCT Innovation Forum focused on interventional heart failure. Noriega detailed how the PSCA System aims to improve patient outcomes for those experiencing cardiogenic shock.
Experiences from the EUREKA FIH Study
In another session led by Professor Petr Neužil, the clinical results were discussed from the EUREKA First-in-Human Study. According to Neužil, the PSCA device was successfully implanted in all five subjects, with an overall encouraging safety profile. Impressively, the device did not lead to any adverse effects related to the procedure.
The Future of PercAssist
As the medical community looks to the future, PercAssist is set to continue its clinical studies. The company is keenly focused on expanding its research to evaluate the PSCA System's potential in treating patients with less severe stages of cardiogenic shock. The innovative device is already showing promising developments that indicate it could provide a needed solution in emergency cardiology.
About PercAssist, Inc.
Founded in 2019 and based in Santa Clara, California, PercAssist aims to transform the management of cardiogenic shock through its advanced PSCA System. The design emphasizes extravascular support without requiring anticoagulation or contrast, minimizing the risks associated with conventional devices. As the company pursues ongoing enrollment in clinical trials, the vision remains steadfast: to offer effective mechanical circulatory support to patients in need.
Frequently Asked Questions
What is the PSCA System?
The PSCA System is an innovative device designed to provide mechanical circulatory support for patients in cardiogenic shock without the need for vascular access.
What were the key outcomes from the TCT24 conference?
PercAssist presented promising results from clinical trials, demonstrating successful device implants and favorable safety profiles.
Who presented at TCT24?
Gerardo Noriega and Professor Petr Neužil showcased the PSCA System during key sessions at the conference.
What is cardiogenic shock?
Cardiogenic shock is a severe medical condition where the heart fails to pump sufficient blood, often leading to serious complications.
How can I learn more about PercAssist?
To find out more about PercAssist and their technology, visit their official website for updates and detailed information.
